2023. Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s134. DOI:https://doi.org/10.25251/skin.7.supp.134.